ASH Reveals Promising Datapoints for Incyte (INCY) - UBS

Two Phase 3 Studies Reinforce Sustained Benefits of Treatment with Jakafi® (ruxolitinib) in Patients with Myeloproliferative Neoplasms (MPNs)

COMFORT-II data demonstrate that patients with myelofibrosis treated with Jakafi achieved a 33 percent reduction in the risk of death after five years

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announces data from two Phase 3 studies evaluating the long-term safety and efficacy of Jakafi® (ruxolitinib) in patients with Myeloproliferative Neoplasms (MPNs). In myelofibrosis (MF), results of a five-year follow-up from the COMFORT-II study demonstrate a continued survival benefit in patients originally randomized to ruxolitinib compared with patients randomized to best available therapy (BAT), with a 33 percent reduction in the... More

Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint

Patients with polycythemia vera without enlarged spleen treated with Jakafi achieved hematocrit control without phlebotomy

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announces the Phase 3 RESPONSE-2 study of Jakafi® (ruxolitinib) met its primary endpoint. Treatment with Jakafi achieved hematocrit control without the need for phlebotomy in patients with inadequately controlled polycythemia vera (PV) resistant to or intolerant of hydroxyurea (HU) who did not have an enlarged spleen, compared to best available therapy (BAT). The safety profile of ruxolitinib was consistent with previous studies.

"The results from the... More